Johnson & Johnson (JNJ) announced the appointment of John Reed, M.D., Ph.D., to the company’s executive committee as Executive Vice President of Pharmaceuticals, R&D. Dr. Reed previously served as Executive Vice President, Global Head of Research and Development for Sanofi (SNY) and "brings more than 35 years of biomedical research leadership to the company," J&J stated. Dr. Reed will join Johnson & Johnson on April 3, assuming responsibility for the company’s portfolio from William Hait, M.D., Ph.D., who has served as interim head of Johnson & Johnson’s Pharmaceutical R&D organization since August 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JNJ:
- Ten Stocks to Buy Before Their Ex-Dividend Dates Arrive
- Roche expands collaboration with Janssen to create companion diagnostics
- Arrowhead price target lowered to $77 from $83 at RBC Capital
- Arrowhead price target lowered to $52 from $55 at Piper Sandler
- Addex Therapeutics completes enrollment in part one of ADX71149 trial